Biomea Fusion (BMEA) vs Fortress Biotech (FBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Biomea Fusion (BMEA) over the past year, losing 30.7% versus a loss of 42.5%. Over five years, BMEA leads with a -92.1% price change compared with -95.8% for FBIO. Biomea Fusion is the larger company by market cap ($62.8 million vs $62.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | FBIO |
|---|---|---|
| Share price | $0.8689 | $1.87 |
| Market cap | $62.82M | $62.37M |
| 1-day change | +3.89% | -2.09% |
| YTD return | -29.93% | -48.91% |
| 1-year return | -42.46% | -30.74% |
| 5-year return | -92.09% | -95.84% |
| P/E ratio (TTM) | — | 0.68 |
| EPS (TTM) | $-0.29 | $2.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $63.26M |
| Revenue growth (YoY) | — | +9.69% |
| Net income (latest FY) | $-61.80M | $6.82M |
| Gross margin | — | 66.92% |
| Operating margin | — | -111.00% |
| Net margin | — | 10.77% |
| 52-week high | $2.24 | $4.53 |
| 52-week low | $0.7995 | $1.84 |
| Distance from 52-week high | -61.16% | -58.72% |
| Analyst consensus | buy | none |
| Avg. price target upside | +705.62% | +167.38% |
| Average volume | 1.93M | 448.52K |
| Shares outstanding | 72.30M | 33.35M |
| Employees | 37 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed BMEA by 11.7 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
BMEA vs FBIO FAQ
Which is bigger, Biomea Fusion or Fortress Biotech?
Biomea Fusion (BMEA) is larger, with a market capitalization of $62.82M compared with $62.37M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, BMEA or FBIO?
FBIO returned -30.74% over the past 12 months, compared with -42.46% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Fortress Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.